Molecular epidemiology and genetic diversity of fluoroquinolone-resistant Escherichia coli isolates from patients with community-onset infections in 30 Chinese county hospitals

Journal of Clinical Microbiology

Volumn 53, Issue 3, 2015, Pages 766-770

  Zhao, Lina ^a   Zhang, Jing ^a   Zheng, Beiwen ^a   Wei, Zeqing ^a   Shen, Ping ^a   Li, Sujuan ^a   Li, Lanjuan ^a   Xiao, Yonghong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; BACTERIAL DNA; ESCHERICHIA COLI PROTEIN; MUTANT PROTEIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CHINA; COMMUNITY ACQUIRED INFECTION; ESCHERICHIA COLI; GENE IDENTIFICATION; GENE MUTATION; GENETIC VARIABILITY; IB CR GENE; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; OQXAB GENE; PHYLOGENY; PLASMID; PMQR GENE; PRIORITY JOURNAL; QEPA GENE; QNR GENE; ANALYSIS; CHEMISTRY; CLASSIFICATION; CLUSTER ANALYSIS; COMMUNITY-ACQUIRED INFECTIONS; DRUG EFFECTS; ESCHERICHIA COLI INFECTIONS; GENETIC VARIATION; GENETICS; GENOTYPE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOLECULAR GENETICS; PUBLIC HOSPITAL;

ESCHERICHIA COLI;

ANTI-BACTERIAL AGENTS; CHINA; CLUSTER ANALYSIS; COMMUNITY-ACQUIRED INFECTIONS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; GENES, BACTERIAL; GENETIC VARIATION; GENOTYPE; HOSPITALS, COUNTY; HUMANS; MOLECULAR EPIDEMIOLOGY; MOLECULAR SEQUENCE DATA; MULTILOCUS SEQUENCE TYPING; MUTANT PROTEINS; PHYLOGENY; PLASMIDS;

EID: 84923372244     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02594-14     Document Type: Article

References (29)

1. Jing CM, Xiao AL, Yan L, Cheng G. 2011. Investigation and analysis on antibacterial drug use in four cities of China. Chin J Pharmacovigilance 8:216-219.
2. Scientific working group. 2009. The indications and rational use of quinolones in the treatment of infectious diseases: a consensus. Chin J Infect Chemother 9:81-88.
3. Xiao YH, Shen P, Wei ZQ, Chen YB, Kong Yang HS Q, Zhang WL, Chen X, Li LJ. 2012. Mohnarin report of 2011: monitoring of bacterial resistance in China. Chin J Nosocomiol 22:4946-4952.
4. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team, Participating National Healthcare Safety Network Facilities. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcareassociated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 29:996-1011. http://dx.doi.org/10.1086/591861.
5. European Centre for Disease Prevention and Control. 2012. Surveillance report: antimicrobial resistance surveillance in Europe 2012. http://www.ecdc.europa.eu/en/publications/-layouts/forms/Publication-DispForm.aspx?List-4f55ad51-4aed-4d32-b960-af70113dbb90&ID-963.
6. Karlowsky JA, Adam HJ, Desjardins M, Lagace-Wiens PR, Hoban DJ, Zhanel GG, Canadian Antimicrobial Resistance Alliance. 2013. Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals. J Antimicrob Chemother 68(Suppl 1):i39-i46. http://dx.doi.org/10.1093/jac/dkt025.
7. Strahilevitz J, Jacoby GA, Hooper DC, Robicsek A. 2009. Plasmidmediated quinolone resistance: a multifaceted threat. Clin Microbiol Rev 22:664-689. http://dx.doi.org/10.1128/CMR.00016-09.
8. Cao X, Cavaco LM, Lv Y, Li Y, Zheng B, Wang P, Hasman H, Liu Y, Aarestrup FM. 2011. Molecular characterization and antimicrobial susceptibility testing of Escherichia coli isolates from patients with urinary tract infections in 20 Chinese hospitals. J Clin Microbiol 49:2496-2501. http://dx.doi.org/10.1128/JCM.02503-10.
9. Yang J, Luo Y, Li J, Ma Y, Hu C, Jin S, Ye L, Cui S. 2010. Characterization of clinical Escherichia coli isolates from China containing transferable quinolone resistance determinants. J Antimicrob Chemother 65:453-459. http://dx.doi.org/10.1093/jac/dkp478.
10. Zhao Q, Wang YP, Ying CM, Zheng B, Zhang HM, Yang J. 2013. A study of plasmid-mediated aac (6=)-Ib gene determination and quinolone resistance. Lab Med 28:199-202.
11. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
12. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. 2007. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother 60:394-397. http://dx.doi.org/10.1093/jac/dkm204.
14. Kim HB, Park CH, Kim CJ, Kim EC, Jacoby GA, Hooper DC. 2009. Prevalence of plasmid-mediated quinolone resistance determinants over a 9-year period. Antimicrob Agents Chemother 53:639-645. http://dx.doi.org/10.1128/AAC.01051-08.
15. Zhao JY, Dang H. 2012. Coastal seawater bacteria harbor a large reservoir of plasmid-mediated quinolone resistance determinants in Jiaozhou Bay, China. Microb Ecol 64:187-199. http://dx.doi.org/10.1007/s00248-012-0008-z.
16. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. 2006. Prevalence in the United States of aac (6=)-Ib-cr encoding a ciprofloxacinmodifying enzyme. Antimicrob Agents Chemother 50:3953-3955. http://dx.doi.org/10.1128/AAC.00915-06.
17. Kim HB, Wang M, Park CH, Kim EC, Jacoby GA, Hooper DC. 2009. oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae. Antimicrob Agents Chemother 53:3582-3584. http://dx.doi.org/10.1128/AAC.01574-08.
18. Gordon DM, Clermont O, Tolley H, Denamur E. 2008. Assigning Escherichia coli strains to phylogenetic groups: multi-locus sequence typing versus the PCR triplex method. Environ Microbiol 10:2484-2496. http://dx.doi.org/10.1111/j.1462-2920.2008.01669.x.
19. Wang H, Chen MJ, Sun HL, Ni YX, Huang XH, Hu ZD, Chu YZ, Yu YS, Liao K, Yu XJ, Mei YN, Sun ZY. 2010. Antimicrobial resistance among nosocomial gram-negative bacilli report from Chinese Meropenem Susceptibility Surveillance in 2008. Chin J Practical Intern Med 30:44-48.
20. Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC. 2003. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother 47:2242-2248. http://dx.doi.org/10.1128/AAC.47.7.2242-2248.2003.
21. Xia S, Fan X, Huang Z, Xia L, Xiao M, Chen R, Xu Y, Zhuo C. 2014. Dominance of CTX-M-type extended-spectrum beta-lactamase (ESBL) - producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS One 9:e100707. http://dx.doi.org/10.1371/journal.pone.0100707.
22. Kang CI, Cha MK, Kim SH, Ko KS, Wi YM, Chung DR, Peck KR, Lee NY, Song JH. 2013. Clinical and molecular epidemiology of communityonset bacteremia caused by extended-spectrum beta-lactamaseproducing Escherichia coli over a 6-year period. J Korean Med Sci 28:998-1004. http://dx.doi.org/10.3346/jkms.2013.28.7.998.
23. Gibreel TM, Dodgson AR, Cheesbrough J, Fox AJ, Bolton FJ, Upton M. 2012. Population structure, virulence potential and antibiotic susceptibility of uropathogenic Escherichia coli from northwest England. J Antimicrob Chemother 67:346-356. http://dx.doi.org/10.1093/jac/dkr451.
24. Colpan A, Johnston B, Porter S, Clabots C, Anway R, Thao L, Kuskowski MA, Tchesnokova V, Sokurenko EV, Johnson JR, VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. 2013. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin Infect Dis 57:1256-1265. http://dx.doi.org/10.1093/cid/cit503.
25. Carlos C, Pires MM, Stoppe NC, Hachich EM, Sato MI, Gomes TA, Amaral LA, Ottoboni LM. 2010. Escherichia coli phylogenetic group determination and its application in the identification of the major animal source of fecal contamination. BMC Microbiol 10:161. http://dx.doi.org/10.1186/1471-2180-10-161.
26. Wang Y, Zhao S, Han L, Guo X, Chen M, Ni Y, Zhang Y, Cui Z, He P. 2 July 2014. Drug resistance and virulence of uropathogenic Escherichia coli from Shanghai, China. J Antibiot (Tokyo). http://dx.doi.org/10.1038/ja.2014.72.
27. CTX-M-15 among extendedspectrumbeta-lactamase-producing E. Coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 56:2364-2370. http://dx.doi.org/10.1128/AAC.05824-11.
28. Oteo J, Diestra K, Juan C, Bautista V, Novais A, Perez-Vazquez M, Moya B, Miro E, Coque TM, Oliver A, Canton R, Navarro F, Campos J, Spanish Network in Infectious Pathology Project (REIPI). 2009. Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. Int J Antimicrob Agents 34:173-176. http://dx.doi.org/10.1016/j.ijantimicag.2009.03.006.
29. Wang GL, Wang MF. 2013. Present situation of residents recognition and medication behaviors of antibiotics and the influencing factors. Chin Gen Pract 16:819-822.